Pfizer to Purchase ReViral, Up To $525M


Pfizer Inc. (NYSE: PFE) is to acquire ReViral Ltd., a Stevenage, UK-based biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).

The deal includes milestones for development and upfront considerations. The transaction is subject to standard closing conditions including the receipt of regulatory approvals.

The acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent illness through vaccination.

ReViral’s CEO Alex C. Sapir has developed a range of therapeutic options, including sisunatovir (an orally administered inhibitor that blocks the fusion of RSV virus and host cells). RSV can be a serious respiratory pathogen that can cause life-threatening lower respiratory infections (LRTIs), in high-risk populations such as infants, immunocompromised persons, and seniors. It causes approximately 64 million infections each year, leading to around 160,000 deaths worldwide.

Sisunatovir reduced the viral load by a significant amount in a phase 2 RSV human test study in healthy adults. It is currently being developed in phase 2 clinical trials in infants. The sisunatovir program is expected to continue in pediatric and adult populations. A second program targets the viral N protein to inhibit RSV replication. This program’s lead candidate is currently in clinical development.

U.S. Food and Drug Administration granted Sisunatovir Fast Track designation. ReViral announced in June 2021 that Part A of the phase 2 REVIRAL1 study sisunatovir to treat RSV infections in infants hospitalized had been completed.

The company had support from CR-CP Life Science Fund and Andera Partners, Brace Pharmaceutical Capital, Brace Pharma Equity, Brace Venture Partners, Green Sands Equity. New Leaf Venture Partners, Novo Holdings. Perceptive Advisors.

Get latest news from African Startup ecosystem

Latest stories

You might also like...